Found 45 articles
Umoja Biopharma, Inc. announced the appointment of Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board.
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round.
Umoja CEO Andy Scharenberg spoke with BioSpace about the company's unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech's most exciting hotbeds.
Pyramid Biosciences, Inc. today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer.
Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced new data at the 2022 iPSC Manufacturing Summit held in Boston, Mass.
Enavate Sciences Appoints Industry Veteran Robert Glassman as Executive Vice President, Search & Evaluation
Enavate Sciences , a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation.
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.
Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have a poster presentation at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, to be held June 15-18, 2022 in San Francisco, California.
Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology
Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
Umoja Biopharma, Inc. and Lupagen, Inc. announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology.
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors.
Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate
Umoja Biopharma, Inc. announced data from three presentations at the American Society of Gene and Cell Therapy Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.
Umoja Biopharma, Inc. announced Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.
Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022
Umoja Biopharma, Inc. announced that it will have an oral presentation at the International Society for Cell and Gene Therapy Annual Meeting 2022, to be held May 4-7, 2022 in San Francisco, California.
Umoja Biopharma, Inc. announced today the Seattle Children’s activation of the Phase 1 ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170.
Umoja Biopharma, Inc. announced that it will have an oral presentation and two posters at the American Society of Gene and Cell Therapy 25th Annual Meeting, to be held May 16-19, 2022.
Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.
Cellevolve Announces Expansive Global Collaboration with Seattle Children’s Therapeutics to Advance Research for Childhood Brain Cancers
Cellevolve Bio (“the Company” or “Cellevolve”), and Seattle Children’s Therapeutics, today announced a collaboration aimed at developing and commercializing a suite of novel multiplex CARs for the treatment of pediatric CNS malignancies.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.